Skip to main content
Erschienen in: Indian Journal of Surgical Oncology 2/2019

18.12.2018 | Original Article

Sentinel Lymph Node Biopsy After Initial Lumpectomy (SNAIL Study)—a Prospective Validation Study

verfasst von: Sanjit Kumar Agrawal, Lalit Bansawal, Indu Arun, Soumtira Shankar Datta, Sanjoy Chatterjee, Rosina Ahmed

Erschienen in: Indian Journal of Surgical Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Tertiary oncology center clinicians are commonly faced with the problem of managing patients with a diagnosis of breast cancer made after lumpectomy in the Primary Health Care (PHC) setting. There are no studies or guidelines that address the further surgical management in this group of patients regarding sentinel lymph node biopsy (SLNB) and need for breast post-operative cavity excision. Prospective observational study was planned to evaluate the feasibility of SLNB and defining the need for definitive breast surgery in patients diagnosed with breast cancer after lumpectomy in PHC. The study was carried out from January 2015 to August 2017 in Tata Medical Center, India, approved by institutional review board (EC/TMC/36/14). Seventy patients who underwent lumpectomy with a definitive histological analysis of breast cancer were included in this study. Each patient had definitive breast surgery and SLNB using subareoral blue dye injection followed by validation axillary dissection. The identification rate (IR) for SLNB was 92% (64/70). The median number of SLNs removed was 2 (IQR 1, 3). There were 2 patients with false negative results resulting in false negative rate (FNR) of 11%. Overall, SLNB procedure has the sensitivity of 89%, NPV of 96%, and accuracy was 97%. Peri-areoral incision of initial surgery was associated with low IR (84%) and high FNR (33%). Final histopathology showed residual invasive cancer in 43% and ductal carcinoma in situ in 14% of patients. Among 21 patients where initial lumpectomy histopathology margin was free of cancer, residual malignancy was found in 57% of patients. Prior excision of lumps for breast cancer does not affect the accuracy of SLNB. Peri-areoral scar may be associated with high FNR and low IR, although further studies are needed to validate this statement. Definitive breast surgery is required for all patients, irrespective of initial lumpectomy histopathological margin status.
Literatur
1.
Zurück zum Zitat Cardoso F, Cataliotti L, Costa A, Knox S, Marotti L, Rutgers E, Beishon M (2017) European Breast Cancer Conference manifesto on breast centres/units. Eur J Cancer 72:244–250CrossRefPubMed Cardoso F, Cataliotti L, Costa A, Knox S, Marotti L, Rutgers E, Beishon M (2017) European Breast Cancer Conference manifesto on breast centres/units. Eur J Cancer 72:244–250CrossRefPubMed
2.
Zurück zum Zitat Feldman SM, Krag DN, McNally RK et al (1999) Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 188:248–254CrossRefPubMed Feldman SM, Krag DN, McNally RK et al (1999) Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg 188:248–254CrossRefPubMed
3.
Zurück zum Zitat Borgstein PJ, Pijpers R, Comans EF et al (1998) Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283CrossRefPubMed Borgstein PJ, Pijpers R, Comans EF et al (1998) Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186:275–283CrossRefPubMed
4.
Zurück zum Zitat Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB 3rd, Bosserman LD, Burstein HJ, Cody H 3rd, Hayman J, Perkins CL, Podoloff DA, Giuliano AE, American Society of Clinical Oncology Clinical Practice (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365–1383CrossRef Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, Benson AB 3rd, Bosserman LD, Burstein HJ, Cody H 3rd, Hayman J, Perkins CL, Podoloff DA, Giuliano AE, American Society of Clinical Oncology Clinical Practice (2014) Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 32:1365–1383CrossRef
5.
Zurück zum Zitat Heuts EM, van der Ent FW, Kengen RA et al (2006) Results of sentinel node biopsy not affected by previous excisional biopsy. Eur J Surg Oncol 32:278–281CrossRefPubMed Heuts EM, van der Ent FW, Kengen RA et al (2006) Results of sentinel node biopsy not affected by previous excisional biopsy. Eur J Surg Oncol 32:278–281CrossRefPubMed
6.
Zurück zum Zitat Celebioglu F, Frisell J, Danielsson R, Bergkvist L (2007) Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol 33:276–280CrossRefPubMed Celebioglu F, Frisell J, Danielsson R, Bergkvist L (2007) Sentinel node biopsy in non-palpable breast cancer and in patients with a previous diagnostic excision. Eur J Surg Oncol 33:276–280CrossRefPubMed
7.
Zurück zum Zitat Noguchi M, Inokuchi M, Zen Y (2009) Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 100:100–105CrossRef Noguchi M, Inokuchi M, Zen Y (2009) Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 100:100–105CrossRef
9.
Zurück zum Zitat Grant RN, Tabah EJ, Adair FE (1953) The surgical significance of the subareolar symph plexus in cancer of the breast. Surgery 33:71–78PubMed Grant RN, Tabah EJ, Adair FE (1953) The surgical significance of the subareolar symph plexus in cancer of the breast. Surgery 33:71–78PubMed
10.
Zurück zum Zitat Quan ML, Wells BJ, McCready D, Wright FC, Fraser N, Gagliardi AR (2010) Beyond the false negative rate: development of quality indicators for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 17:579–591CrossRefPubMed Quan ML, Wells BJ, McCready D, Wright FC, Fraser N, Gagliardi AR (2010) Beyond the false negative rate: development of quality indicators for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 17:579–591CrossRefPubMed
11.
Zurück zum Zitat Acuna SA, Angarita FA, McCready DR, Escallon J (2013) Quality indicators for sentinel lymph node biopsy: is there room for improvement? Can J Surg 56:82–88CrossRefPubMedPubMedCentral Acuna SA, Angarita FA, McCready DR, Escallon J (2013) Quality indicators for sentinel lymph node biopsy: is there room for improvement? Can J Surg 56:82–88CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Agrawal SK, Shenoy SS, Nalawade N, Datta SS, Roy S, Chatterjee S, Arun I, Ahmed R (2018) Quality indicators for sentinel lymph node biopsy in breast cancer: applicability and clinical relevance in a non-screened population. Indian J Surg Oncol 9(3):312–317. https://doi.org/10.1007/s13193-017-0695-5 Agrawal SK, Shenoy SS, Nalawade N, Datta SS, Roy S, Chatterjee S, Arun I, Ahmed R (2018) Quality indicators for sentinel lymph node biopsy in breast cancer: applicability and clinical relevance in a non-screened population. Indian J Surg Oncol 9(3):312–317. https://​doi.​org/​10.​1007/​s13193-017-0695-5
13.
Zurück zum Zitat Ung OA (2004) Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg 27:284–290CrossRefPubMed Ung OA (2004) Australasian experience and trials in sentinel lymph node biopsy: the RACS SNAC trial. Asian J Surg 27:284–290CrossRefPubMed
14.
Zurück zum Zitat Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–609CrossRef Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98:599–609CrossRef
15.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready D, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRef Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready D, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881–888CrossRef
16.
Zurück zum Zitat Zavagno G, De Salvo GL, Scalco G et al (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247:207–213CrossRefPubMed Zavagno G, De Salvo GL, Scalco G et al (2008) A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247:207–213CrossRefPubMed
17.
Zurück zum Zitat Smith MJ, Gill PG, Wetzig N et al (2009) Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat 117:99–109CrossRefPubMed Smith MJ, Gill PG, Wetzig N et al (2009) Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Res Treat 117:99–109CrossRefPubMed
18.
Zurück zum Zitat Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, Carli F, Bruzzi P, Dozin B (2009) Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 20:1001–1007CrossRefPubMed Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, Carli F, Bruzzi P, Dozin B (2009) Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 20:1001–1007CrossRefPubMed
19.
Zurück zum Zitat Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, de Cicco C, Vezzoli D (2010) Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 251:595–600CrossRefPubMed Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, de Cicco C, Vezzoli D (2010) Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg 251:595–600CrossRefPubMed
20.
Zurück zum Zitat Renaudeau C, Lefebvre-Lacoeuille C, Campion L, Dravet F, Descamps P, Ferron G, Houvenaeghel G, Giard S, Tunon de Lara C, Dupré PF, Fritel X, Ngô C, Verhaeghe JL, Faure C, Mezzadri M, Damey C, Classe JM (2016) Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast 28:54–59CrossRefPubMed Renaudeau C, Lefebvre-Lacoeuille C, Campion L, Dravet F, Descamps P, Ferron G, Houvenaeghel G, Giard S, Tunon de Lara C, Dupré PF, Fritel X, Ngô C, Verhaeghe JL, Faure C, Mezzadri M, Damey C, Classe JM (2016) Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast 28:54–59CrossRefPubMed
21.
Zurück zum Zitat Coskun G, Dogan L, Karaman N, Ozaslan C, Atalay C (2012) Value of sentinel lymph node biopsy in breast cancer patients with previous excisional biopsy. J Breast Cancer 15:87–90CrossRefPubMedPubMedCentral Coskun G, Dogan L, Karaman N, Ozaslan C, Atalay C (2012) Value of sentinel lymph node biopsy in breast cancer patients with previous excisional biopsy. J Breast Cancer 15:87–90CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, Laidley AL, McGlothin TQ, Ley PB, Brown CM, Glaser RL, Pennington RE, Turk PS, Simpson D, McMasters KM, the University of Louisville Breast Cancer Study Group (2002) The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 9:272–277CrossRefPubMed Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, Laidley AL, McGlothin TQ, Ley PB, Brown CM, Glaser RL, Pennington RE, Turk PS, Simpson D, McMasters KM, the University of Louisville Breast Cancer Study Group (2002) The effect of prior breast biopsy method and concurrent definitive breast procedure on success and accuracy of sentinel lymph node biopsy. Ann Surg Oncol 9:272–277CrossRefPubMed
23.
Zurück zum Zitat Haigh PI, Hansen NM, Qi K, Giuliano AE (2000) Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 7:21–27CrossRefPubMed Haigh PI, Hansen NM, Qi K, Giuliano AE (2000) Biopsy method and excision volume do not affect success rate of subsequent sentinel lymph node dissection in breast cancer. Ann Surg Oncol 7:21–27CrossRefPubMed
24.
Zurück zum Zitat Golshan M, Nakhlis F (2006) Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J 12:428–430CrossRefPubMed Golshan M, Nakhlis F (2006) Can methylene blue only be used in sentinel lymph node biopsy for breast cancer? Breast J 12:428–430CrossRefPubMed
25.
Zurück zum Zitat East JM, Valentine CS, Kanchev E et al (2009) Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg 9:2CrossRefPubMedPubMedCentral East JM, Valentine CS, Kanchev E et al (2009) Sentinel lymph node biopsy for breast cancer using methylene blue dye manifests a short learning curve among experienced surgeons: a prospective tabular cumulative sum (CUSUM) analysis. BMC Surg 9:2CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Chagpar A, Martin RC 3rd, Chao C et al (2004) Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 139:614–618; discussion 618–20CrossRefPubMed Chagpar A, Martin RC 3rd, Chao C et al (2004) Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 139:614–618; discussion 618–20CrossRefPubMed
27.
Zurück zum Zitat Chatterjee S, Arunsingh M, Agrawal S, Dabkara D, Mahata A, Arun I et al (2016) Outcomes following a moderately hypofractio-nated adjuvant radiation (START B Type) schedule for breast cancer in an unscreened non-Caucasian population. Clin Oncol 28:e165ee172CrossRef Chatterjee S, Arunsingh M, Agrawal S, Dabkara D, Mahata A, Arun I et al (2016) Outcomes following a moderately hypofractio-nated adjuvant radiation (START B Type) schedule for breast cancer in an unscreened non-Caucasian population. Clin Oncol 28:e165ee172CrossRef
28.
Zurück zum Zitat Thorat MA, Rangole A, Nadkarni MS, Parmar V, Badwe RA (2008) Revision surgery for breast cancer: single-institution experience. Cancer 113:2347–2352CrossRefPubMed Thorat MA, Rangole A, Nadkarni MS, Parmar V, Badwe RA (2008) Revision surgery for breast cancer: single-institution experience. Cancer 113:2347–2352CrossRefPubMed
29.
Zurück zum Zitat Ebner F (2017) To clip or not to clip the breast tumor bed? A retrospective look at the geographic miss index and normal tissue index of 110 patients with breast cancer. J Turk Ger Gynecol Assoc 18:67–71CrossRefPubMedPubMedCentral Ebner F (2017) To clip or not to clip the breast tumor bed? A retrospective look at the geographic miss index and normal tissue index of 110 patients with breast cancer. J Turk Ger Gynecol Assoc 18:67–71CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M (2007) Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In vivo 21:673–678PubMed Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M (2007) Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In vivo 21:673–678PubMed
31.
Zurück zum Zitat Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G et al (2010) ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer 47:8–15CrossRefPubMed Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G et al (2010) ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer 47:8–15CrossRefPubMed
Metadaten
Titel
Sentinel Lymph Node Biopsy After Initial Lumpectomy (SNAIL Study)—a Prospective Validation Study
verfasst von
Sanjit Kumar Agrawal
Lalit Bansawal
Indu Arun
Soumtira Shankar Datta
Sanjoy Chatterjee
Rosina Ahmed
Publikationsdatum
18.12.2018
Verlag
Springer India
Erschienen in
Indian Journal of Surgical Oncology / Ausgabe 2/2019
Print ISSN: 0975-7651
Elektronische ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-018-0861-4

Weitere Artikel der Ausgabe 2/2019

Indian Journal of Surgical Oncology 2/2019 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.